bluuebunny/crossref_metadata_2025 huggingface dataset:
430. Impact of a Pharmacist-Managed Sexually Transmitted Disease (STD) Test Result Review Service at a Veterans Affairs Medical Center
Authors: Dayo Yewande , Ashong Chester , Hunter Andrew , Rodriguez-Barradas Maria C
Published: October 2019

Background

The CDC recommends annual STD screenings in all sexually active women ³25 years old and men who have sex with men. Given the increased incidence of STDs and the need to improve their management, in September 2018 infectious diseases clinical pharmacists implemented a pharmacist-managed STD quality improvement project (QI) that reviewed positive STD test results with feedback to providers. We present the results of this QI project below.

Methods

The QI project consisted of prospective, daily reviews of all positive chlamydia, gonorrhea or syphilis tests (post-implementation period: 9/2018 to 2/2019). Patient electronic medical records were reviewed and assessed for the need for additional laboratory tests and to determine whether appropriate treatment was received, with feedback provided to the primary provider. In addition, risk factors were assessed to determine the appropriateness of human immunodeficiency virus (HIV) Pre-Exposure Prophylaxis (PrEP). A retrospective review of positive STD results from 9/2017 to 2/2018 was also conducted (pre-implementation period) for comparison. The purpose of this project was to evaluate the impact of pharmacist test result review on the appropriate testing, review appropriateness of prescribed treatments of patients diagnosed with any STD according to accepted clinical guidelines, and to inform the need for and the areas of focus for educating providers in the emergency room and primary care clinics on the management of these patients. Descriptive statistics, Chi square, and Fisher’s exacts tests were used to analyze the outcomes of the project.

Results

A total of 144 patients were included in the project (pre-implementation, n = 47; post-implementation n = 74). Please refer to the table for other results.

Conclusion

The implementation of a pharmacist-managed STD test review service decreased time to treatment and time to STD test result review. More patients in the post-implementation period received appropriate therapy compared with patients in the pre-intervention period. These findings indicate that there is a role for a pharmacist-managed STD test review service in assisting providers with quickly and appropriately connecting patients to care.

Disclosures

All authors: No reported disclosures.
433. Implementation of an Emergency Department Syphilis Screening Program
Authors: Chechi Tasleem , Sage Allyson C , Tran Nam , Waldman Sarah , May Larissa S
Published: October 2019

Background

Syphilis incidence across all regions of California increased by 22% compared with 2016 cases; with the largest number of chlamydia, gonorrhea, syphilis, and congenital syphilis cases among all states (CDC 2017). The USPSTF recommends targeted syphilis screening in patients at increased risk. However, in emergency departments (EDs) targeted syphilis screening is not routinely performed even when patients present for concerns of a sexually transmitted infection (STI). The purpose of this program was to implement routine syphilis screening among ED patients being tested for chlamydia and gonorrhea (CT/GC) through the use of an EHR enhancement to maximize the number of new syphilis diagnoses.

Methods

From November 27, 2018 to March 31, 2019, EHR-based syphilis screening was implemented in a quaternary care ED in Northern California serving urban and rural populations. EMR best practice alerts (BPA) were developed and populated on patients receiving STI testing. Syphilis testing employed a reverse sequence algorithm, which is suggested for high prevalence settings and provides rapid turnaround time. Patients were excluded if they opted out from testing. We determined the proportion of all CT/GC tested patients who underwent syphilis screening and the prevalence of syphilis among this group.

Results

During a four-month period, 649 ED patients with suspected STI received a BPA to screen for syphilis. Of those, 425 patients (65.5%) were screened for syphilis, 22 had a reactive IgG/IgM and RPR, while 5 patients had a reactive IgG/IgM and a nonreactive RPR which required a TPPA test to detect their infection. Fourteen of the 22 patients with a reactive RPR had titers of 1:32 or higher. Nine (32%) of those with a positive CT/GC test tested positive for syphilis.

Conclusion

Implementation of a syphilis screening program in patients undergoing testing for other STIs yielded 28 new diagnoses compared with those tested prior to the screening in 2018. Introducing an automated EMR-based syphilis screening program is an effective method to maximize syphilis screening in all ED patients seeking treatment for STIs. The screening data suggest that the majority of patients undergoing STI testing in our ED are not screened for syphilis, yet the prevalence of infection in those screened is substantial.

Disclosures

All authors: No reported disclosures.
451. High Rates of Hospitalization due to Skin and Soft-Tissue Infections in a Southwest American Indian Population
Authors: Davidson Anne M , Burgess Terry , Saguros Agafe , Jian Ma Chu , McAuley James , Close Ryan M
Published: October 2019

Background

Skin and soft-tissue infections (SSTIs) involve the skin, subcutaneous tissue, fascia, or muscle. Hospitalizations due to SSTIs represent a significant health disparity for American Indians (AI), but specific literature is limited. We characterized SSTI hospitalizations at our critical access hospital that exclusively serves an AI population in the American Southwest.

Methods

We identified patients hospitalized (admitted or transferred) with an SSTI from June 2017 to May 2018. Relevant cases underwent chart extraction for demographics, SSTI characteristics, laboratory and microbiologic data, relevant history and co-morbidities. All variables were summarized using descriptive statistics. Odds ratios and P-values with two-tailed tests were used to identify risk factors for multiple SSTI episodes.

Results

During the study period, 289 unique individuals comprised 343 SSTI hospitalizations / episodes (18% of the 1,883 total hospitalizations). The unadjusted annual rate of SSTI hospitalization was 2,018 per 100,000. There were 13 cases of necrotizing fasciitis (NF) with an unadjusted rate of 76 per 100,000 per year. Only 183 episodes (53%) had a wound culture performed, with 84% positive for a pathogenic organism, compared with 287 episodes (84%) with a blood culture performed, of which only 7% were positive for a pathogen. Methicillin-resistant Staphylococcus aureus (MRSA), methicillin-sensitive SA (MSSA)and/or Streptococcus pyogenes accounted for 74.9% (n = 125) and co-infection with these three organisms accounted for 22.2% (n = 37) of positive wound cultures (n = 167). An SSTI in the last year (49%), diabetes (41.9%), alcohol abuse (40%) and hypertension (39%) were common among all 289 individuals. Diabetes (OR 3.3, P < 0.01), hypertension (OR 2.8, P < 0.01), renal disease (OR 2.7, P < 0.05), previous SSTI (OR 3.0, P < 0.01) were associated with a higher risk of multiple SSTI hospitalizations.

Conclusion

The incidence rate of SSTI hospitalization in this Southwest AI population was 9-times greater than the general US population and 4-times greater than prior reports in Southwest AI. The NF rate was >10-times the general US population rate. We describe common co-morbidities among these SSTI episodes and potential risk factors for repeat hospitalization.

Disclosures

All authors: No reported disclosures.
454. Perinatal Risk Factors Associated with Skin Infection Hospitalisation in Western Australian Aboriginal and Non-Aboriginal Children
Authors: Barnes Rosanne , Bowen Asha C , Walker Roz , Tong Steven Y C , McVernon Jodie , Campbell Patricia T , Fathima Parveen , de Klerk Nicholas , Wu Yue , Blyth Christopher C , Carapetis Jonathan R , Moore Hannah C
Published: October 2019

Background

Hospitalisation with skin infection in Western Australian (WA) Aboriginal children is common, with the highest rates in infants and children from remote WA. We aimed to quantify infant, maternal, and sociodemographic risk factors for skin infection hospitalization in WA children, focusing on Aboriginal children aged <17 years.

Methods

We conducted a retrospective population-based cohort study with linked perinatal and hospitalization data on WA-born children (1996–2012), of whom 31,348 (6.7%) were Aboriginal. We used Cox regression to calculate adjusted hazard ratios and associated population attributable fractions (PAFs) for perinatal factors attributed to the first hospitalization with skin infection. To identify specific risk factors for early-onset infection, we further restricted the cohort to infants aged <1 year.

Results

Overall, 5,439 (17.4%) Aboriginal and 6,750 (1.5%) non-Aboriginal children were hospitalized at least once with a skin infection. Aboriginal infants aged <1 year had the highest skin infection hospitalization rate (63.2/1,000 child-years). The strongest risk factors in Aboriginal children aged <17 years were socio-economic disadvantage, very remote location at birth and multi-parity (≥3 previous pregnancies) accounting for 24%, 23% and 15% of skin infection hospitalizations, respectively. Other risk factors included maternal age <20 years, maternal smoking during pregnancy and low birthweight.

Conclusion

We have quantified the relative influence of perinatal risk factors associated with skin infection hospitalizations in WA children, providing measures indicating which factors have the potential to reduce the most hospitalizations. Our evidence supports existing calls for substantial government investment in addressing underlying social and environmental barriers to healthy skin in WA Aboriginal children but also identifies potential areas to target health promotion messaging at individuals/families on maternal smoking during pregnancy and skin hygiene for families.

Disclosures

All authors: No reported disclosures.
459. Gaps in Diabetic Foot Care in an Inner-City Hospital
Authors: Schechter Marcos C , Fayfman Maya , SMF. Khan Lubna , Patterson Sierra , Ziemer David , Umpierrez Guillermo , Rajani Ravi , Kempker Russell R
Published: October 2019

Background

Diabetic foot disease is the leading cause of preventable limb loss in the United States. Care continuum models to measure gaps in care are lacking.

Methods

Retrospective cohort study conducted in an urban safety-net hospital in Atlanta, GA (Grady Memorial Hospital). All patients admitted between January-May 2016 with diabetes-related foot ulcer, osteomyelitis, or for lower-extremity amputation were included. A care continuum model for inpatient and post-discharge outpatient metrics was developed based on national guidelines and available diabetes care continuum models (figure). We followed patients for 12 months after initial hospital admission.

Results

Among 123 patients, the median age was 56 (IQR 48–64) years and most were male (67%) and black (83%) (table). Prior to hospital admission, 12% of patients had a major amputation (above ankle) and 21% had a minor amputation (below ankle). Tobacco use (34%), homelessness (29%), and no medical insurance (20%) rates were high. Few patients (28%) had hemoglobin A1c (Hb1Ac) at goal (≤7.5%) and 10% had end-stage renal disease. Regarding inpatient care metrics, 59% had a median glucose at goal on the day of discharge (≤180 gm/dL). Few patient patients had a noninvasive vascular test (13%) or received a wound offloading device (16%) during hospitalization. Regarding post-discharge outpatient metrics, 33% had wound care ≤30 days after hospitalization, 14% with tobacco use at baseline quit, and 24% had Hb1c ≤7.5%. Emergency room (ER) visits and hospital readmissions within 12 months post-discharge were common (77% and 66%, respectively). Only 54% were retained in care (≥2 clinic visits ≥90 days apart). Outcomes during 12 months after the first day of initial hospital admission were poor: 6% died, 23% had a new major amputation and 22% had a new minor amputation. Including major amputations prior to initial hospital admission, 37% of patients died or were living with a major amputation 12 months after hospitalization.

Conclusion

Our care continuum model demonstrated large gaps in diabetic foot care. Over a third of these patients died or were living with major limb loss and there were high rates of ER visits and hospital readmissions. Implementing measures to close gaps in care could improve outcomes.

Disclosures

All authors: No reported disclosures.
466. Elevated Risk of Invasive Group B Streptococcal Infection Among Veterans with Poorly Controlled Diabetes Mellitus or at Extremes for Body Mass Index
Authors: Wilson Brigid , Zappernick Taissa , Banks Richard , Baechle2; Janet Briggs Daniel , Song Sunah , Perez Federico , Jump Robin L
Published: October 2019

Background

Diabetes mellitus (DM) and obesity have been identified as risk factors for invasive Group B Streptococcal (GBS) infection in non-pregnant adults. We used data from the US Veterans Health Administration (VHA) to confirm these findings and determine if poor diabetic control (elevated hemoglobin A1C (HbA1c)) or extreme weight (body mass index (BMI)) impacted risk.

Methods

We examined the VHA Corporate Data Warehouse to identify veterans active in VHA between 2008 and 2017 with invasive GBS infection according to the US Centers for Disease Control and Prevention surveillance definitions. We used International Classification of Disease (ICD) codes to determine a diagnosis of DM and stratified veterans by the highest HbA1c and first BMI in a given year. Absent HbA1c among those with DM were recorded as such. For years without BMI, the most recent BMI was carried forward.

Results

Between 2008 and 2017, the rate of invasive GBS infection for veterans with HbA1C ≥9.5% ranged from 55 to 104 /100,000 person-years (Figure 1). Rates in the next-highest risk group (HbA1c 7.5%–9.4%) were 24 to 36/100,000 person-years. Veterans with a BMI ≥40 (extremely obese; n = 798) or ≤18.5 (underweight; n = 99) had similarly elevated rates of invasive GBS infection (26 to 37/100,000 and 15 to 33/100,000 person-years, respectively) while those with BMI of 18.5–40 ranged from 6 to 13/100,000 person-years (Figure 2). Among those with HbA1c ≥9.5%, the most common type of infection was osteomyelitis (500/1,182; 42%; Table 1). Pneumonia was most common among patients with a BMI, Table 2.

Conclusion

Our study confirms that DM and obesity are notable risk factors for invasive GBS infection among veterans. The risk is substantially increased in patients with poorly controlled DM and morbid obesity. The high rate of invasive GBS infections among the small proportion of underweight veterans may reflect long-standing type 1 DM or other chronic diseases. Effective interventions to reduce the burden of invasive GBS infection among veterans should target individuals with poorly controlled DM, morbid obesity and those markedly underweight.

Disclosures

All authors: No reported disclosures.
484. Metallo-β-Lactamase-Positive Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa in the Antibiotic Resistance Laboratory Network, 2017–2018
Authors: Brown Allison C , Malik Sarah , Huang Jennifer , Bhatnagar Amelia , Balbuena Rocio , Reese Natashia , Lonsway David , Karlsson Maria
Published: October 2019

Background

Infections with metallo-β-lactamase (MBL)-producing organisms are emerging in the United States. Treatment options for these infections are limited. We describe MBL genes among carbapenemase positive carbapenem-resistant Enterobacteriaceae (CP-CRE) and Pseudomonas aeruginosa (CP-CRPA) isolates tested during the first two years of the Antibiotic Resistance Laboratory Network (AR Lab Network).

Methods

State and local public health laboratories tested CRE and CRPA isolates for organism identification, antimicrobial susceptibility, and PCR-based detection of blaKPC, blaNDM, blaOXA-48-like, blaVIM, and blaIMP carbapenemase genes. All testing results were sent to CDC at least monthly.

Results

Since January 2017, the AR Lab Network tested 21,733 CRE and 14,141 CRPA. CP-CRE were detected in 37% of CRE; 2% of CRPA were CP-CRPA. Among CP-CRE, 9% (686/8016) were MBL-producers (NDM, VIM, or IMP). Among MBL-producers, a blaNDM gene was detected most often (81%; 551/686). blaNDM were most common among Klebsiella spp. (47%; 261/551), blaIMP were most common among Providencia spp. (53%; 40/75), blaVIM was most common among Enterobacter spp. (19%; 25/62). Twelve percent (96) of MBL CP-CRE contained more than one carbapenemase gene. Among CP-CRPA, 73% (218/300) were MBL producers and blaVIM was the most common gene (62%; 186). Three (1%) MBL CP-CRPA contained more than one carbapenemase.

Conclusion

Increased testing of CRE and CRPA isolates through the AR Lab Network has facilitated early and rapid detection of hard-to-treat infections caused by MBL-producing organisms across the United States. The widespread distribution of MBL genes highlights the continued need for containment strategies that help prevent transmission between patients and among healthcare facilities. To support therapeutic decisions for severe infections caused by MBL-producing organisms, the AR Lab Network is now offering rapid susceptibility testing against aztreonam/avibactam, using digital dispenser technology. This testing program aims to close the gap between the availability of new drugs or drug combinations and the availability of commercial AST methods, thereby improving patient safety and antimicrobial stewardship.

Disclosures

All authors: No reported disclosures.
493. Laboratory Evaluation and Epidemiology of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Department of Veterans Affairs, 2017
Authors: Pfeiffer Christopher , Williams Holly B , Flegal Hannah , Klutts J Stacey , Evans Martin , Evans Martin , Jones Makoto M
Published: October 2019

Background

Carbapenemase-producing (CP)-carbapenem-resistant Enterobacteriaceae (CRE) pose a major threat to public health and are a priority target of national prevention and control efforts including within Department of Veterans Affairs (VA). The laboratory evaluation and epidemiology of CRE in VA is uncertain.

Methods

Using data from the Veterans Health Administration Corporate Data Warehouse, we identified all Veterans with ≥1 CRE result obtained during 2017 and reviewed their electronic health record. Two case definitions were used: (1) 2015 CDC CRE (Enterobacteriaceae resistant to any carbapenem or with documented carbapenemase production) and (2) 2017 VA CP-CRE (E. coli, Klebsiella spp., and Enterobacter spp. resistant to imipenem, meropenem, or doripenem or with documented carbapenemase production). Patients harboring carbapenemase-producers detected by rectal screening tests only were included. We reviewed patient charts whose isolates met both CRE definitions, extracting detailed microbiologic and travel data for the first positive 2017 result.

Results

We identified 904 unique Veterans with CRE; 577 (64%) patients had results meeting both CRE case definitions while 327 (36%) had results meeting CDC CRE criteria only (Figure 1). Of the 458 patients with clinical isolates meeting both case definitions, urine specimens predominated (64%) and were associated with the lowest crude 90-day mortality (16%); mortality was highest amongst patients with respiratory tract cultures (40%) and bloodstream isolates (34%) (Figure 2). Nearly half (48%) of VA CP-CRE were tested for carbapenemases (76% in-house; 24% send-out); of these, 75%tested positive with 78% being a KPC, 1% NDM, and 21% unspecified (Figure 3). Additionally, all 119 CRE carriers with an identified gene had KPC. Only 7 patients (1%) had documented overseas travel.

Conclusion

Currently the incidence of CP-CRE in the nation’s largest healthcare system is low relative to other problem pathogens such as MRSA and Clostridioides difficile but is associated with a high crude mortality especially with respiratory and bloodstream isolates. KPC comprised almost all carbapenemases identified. This provides an initial, granular snapshot of CRE in VA to serve as a roadmap for ongoing CP-CRE prevention and control.

Disclosures

All authors: No reported disclosures.
498. High Burden of CRO Colonization and Its Association with Infection Among Patients transferred to a Tertiary Care Hospital in India
Authors: Sarma Smita , Robinson Matthew , Mehta Yatin
Published: October 2019

Background

Infections with carbapenem-resistant organisms (CRO) are increasing worldwide and are associated with high mortality. Patients transferred from outside hospitals have been reported to be at increased risk of CRO colonization and infection. The rate of subsequent CRO infection in patients colonized with CRO is unclear in a high CRO burden setting

Methods

Medanta Hospital in Gurgaon, India instituted CRO colonization screening for patients transferred from outside hospitals for infection control purposes. From April 2018 to May 2018, patients transferred from other hospitals to the intensive care unit at Medanta were subjected to CRO colonization screening using Xpert Carba R (Cepheid) performed on the day of transfer. Subsequent recovery of CRO in cultures of blood, bronchoalveolar lavage fluid, urine in specimens with pyuria obtained from patients without urinary catheters, pus, and tissue were considered to be indicative of CRO infection. The association of CRO colonization with subsequent CRO infection was assessed with a Fisher exact test

Results

Among 457 patients screened, 205 patients (45%) were found to be colonized with CRO at admission. Genes for New Delhi Metallo-β-lactamase (NDM) were detected in 184 (40%) patients, OXA-48 in 97 (21%) patients, VIM in 18 (4%) patients, KPC in 5 (1%) patients, and IMP1 in 5 (1%) patients; >1 carbapenemase gene was detected in 95 (21%) patients. CRO infections were observed in 25 (5%) patients including 12 with bacteremia, 7 with pneumonia, 4 with urinary tract infection, and 2 with soft-tissue infection. Among patients with CRO colonization, 17 (8%) patients developed CRO infection during the course of hospitalization; among patients without admission CRO colonization, subsequent CRO infection was found in 8 (3%) patients. CRO admission colonization was associated with subsequent clinical infection with CRO (odds ratio = 2.8, P = 0.02)

Conclusion

CRO colonization was found in almost half of patients transferred from outside hospitals to a large tertiary care hospital in India and was associated with subsequent CRO infection. Further work is necessary to understand the role of CRO colonization screening in infection control and antimicrobial stewardship in a setting with high CRO burden

Disclosures

All authors: No reported disclosures.
501. Risk of Infection in Persons Colonized with Carbapenemase-Producing Enterobacteriales (CPE) in Ontario, Canada
Authors: Faheem Amna , Jamal Alainna , Kazi Hassan , Coleman Brenda , Farooqi Lubna , Johnstone Jennie , Katz Kevin , Li Angel , Melano Roberto , Mubareka Samira , Muller Matthew P , Patel Samir , Paterson Aimee , Poutanen Susan , Rebbapragada Anu , Richardson David , Sarabia Alicia , Zhong Zoe , McGeer Allison
Published: October 2019

Background

We aimed to assess the risk of subsequent infection among patients colonized by CPE.

Methods

The Toronto Invasive Bacterial Diseases Network (TIBDN) has conducted population-based surveillance for CPE colonization/infection in Toronto and Peel region, Ontario, Canada, since CPE were first identified (2007). All laboratories report all CPE isolates to TIBDN. Clinical data are collected via patient interview and hospital chart review. Initially colonized patients are followed for 5y; subsequent CPE infection is defined as an episode with onset >3 days after initial detection of CPE colonization that meets National Healthcare Safety Network criteria for infection with a clinical isolate of CPE.

Results

From 2007 to 2018, 790 persons with CPE colonization/infection were identified. Among 364 cases colonized at identification, 42 (12%) subsequently had at least one clinical isolate, and 23 (6%) had an infection: 8 with bacteremia (primary or secondary), 7 UTI, 5 pneumonia, and 3 other. The median time from identification of colonization to infection was 21 days (IQR 7–38), with a probability of developing an infection of 7% at 3 months, and 18% by 3 years (figure). In 305 cases with data available to date, older persons, those admitted to the ICU, and those with current/recent invasive medical devices were more likely to develop infection (table). Gender, underlying conditions and other procedures were not associated with risk of infection. There was a trend to infections being more likely in patients colonized with K. pneumoniae (52% vs. 35%, P = 0.13).

Conclusion

The risk of subsequent infection in our cohort was 18%, with highest risk in the first 3 months; most infections occurred in patients requiring intensive care unit admission and invasive medical devices.

Disclosures

All authors: No reported disclosures.
504. Epidemiology of End-stage Renal Disease (ESRD) Patients with Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: Atlanta Metropolitan Area, 2012–2017
Authors: Hurd Jacqueline M , Bower Chris W , Jacob Jesse T
Published: October 2019

Background

Patients with end-stage renal disease (ESRD) have higher risks for resistant organisms including carbapenem-resistant Enterobacteriaceae (CRE). To explore the effect of ESRD on CRE, we compared characteristics of CRE cases with and without ESRD in a population-based cohort.

Methods

The Georgia Emerging Infections Program has performed active laboratory- and population-based surveillance for CRE in metropolitan Atlanta (4.1 million in 2017) since 2012. CRE cases are defined by isolation from a sterile body site or urine of E. coli, K. pneumoniae, K. oxytoca, K. aerogenes, or E. cloacae. From 2012 to 2015, cultures were resistant to all third-generation cephalosporins tested and non-susceptible to ≥1 carbapenem (excluding ertapenem). After 2016, cultures were resistant to ≥1 carbapenems. Epidemiologic data including ESRD were collected via medical chart review. ESRD population data were obtained from the US Renal Data System. Georgia vital records data were used to determine 90-day mortality rates. Prevalence estimates were calculated. Comparisons used a χ 2 test.

Results

Of 1,511 CRE cases, 136 (9%) were on current chronic dialysis, 128 (94%) of which were on hemodialysis (HD) and 5 (4%) were on peritoneal dialysis. Among CRE cases with HD, 94 (73%) had a catheter and 30 (23%) had an arteriovenous fistula or graft. CRE cases with ESRD were more likely to be male (58% vs. 40%), black (76% vs. 38%), and have diabetes (67% vs. 38%), congestive heart failure (25% vs. 17%), or peripheral arterial disease (12% vs. 4%). CRE cases with ESRD had more hospitalizations within 30 days of the culture date (77% vs. 47%), ICU admissions prior to (29% vs. 7%) or after the culture date (43% vs. 14%) and discharges to LTCFs (35% vs. 15%) after hospitalization. CRE cases with ESRD and bacteremia were more likely to have been hospitalized >3 days before the culture compared with CRE cases with ESRD and positive cultures from other body sites (52% vs. 24%). The 90-day mortality rate per 100,000 population was higher among CRE cases with ESRD (100.9 cases) than without ESRD (1.0 cases).

Conclusion

Among a population-based cohort of patients with CRE infections, ESRD comprised ~10% but had markedly mortality, suggesting that future interventions should target ESRD.

Disclosures

All authors: No reported disclosures.
508. Gentamicin Non-susceptibility is Associated with Persistence of Carbapenem-Resistant Klebsiella pneumoniae in the Urinary Tract
Authors: Luterbach Courtney , Henderson Heather , Cober Eric , Richter Sandra S , Salata Robert A , Kaye Keith S , Doi Yohei , Watkins Richard R , Bonomo Robert A , van Duin David
Published: October 2019

Background

Urinary tract infection (UTI) is the most common clinical manifestation of carbapenem-resistant Klebsiella pneumoniae (CRKp). Persistent CRKp bacteriuria is associated with the spread of CRKp and antibiotic overuse. Risk factors for persistent CRKp bacteriuria are uncertain.

Methods

CRACKLE-1 was a multicenter, prospective study that included 960 patients with at least one carbapenem-resistant Enterobacteriaceae (CRE)-positive culture from December 2011 to June 2016 collected from 18 hospitals encompassing 8 healthcare systems in the Midwestern US and North Carolina. Patients with CRKp bacteriuria who were discharged alive from index hospitalization were included in the current study, and sporadic (single positive CRKp urine culture) and persistent (≥2 CRKp urine cultures during independent hospital admissions occurring at least 2 days apart) cases were compared. Antibiotic susceptibility testing was performed by local laboratories. Amikacin, gentamicin (GENT), and trimethoprim/sulfamethoxazole were included in the analysis based on variance and frequency of testing. The CDC/National Healthcare Safety Network criteria for UTI were used.

Results

CRKp was the most common CRE isolate (n = 869, prevalence 91%). In patients with CRKp, 527 had CRKp isolated from the urine (prevalence 61%, 95% CI 0.57, 0.64). Of these, 486 patients, of whom 129 (27%) were diagnosed with a UTI, were discharged alive. Notably, 135/486 (28%) patients with CRKp bacteriuria were readmitted and yielded a second urine culture of CRKp. Most patients with persistent bacteriuria, 99/135 (73%), were asymptomatic at initial admission. Of these patients, 20/99 (20%) were diagnosed with a UTI at second admission. In multivariable analysis, only GENT non-susceptibility was associated with an increased risk (adjusted OR 1.66, 95% CI 1.10–2.49) of persistent bacteriuria. Persistent bacteriuria was independent of GENT treatment during index hospitalization (GENT was used in 15% of patients).

Conclusion

Bacteriuria with GENT non-susceptible CRKp strains was associated with persistent bacteriuria. As this was independent of GENT treatment, GENT resistance determinants may be co-transmitted along with traits that promote bacterial persistence in CRKp.

Disclosures

All authors: No reported disclosures.
518. Comparing the Mortality of Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia
Authors: Seo Hyeonji , Yang Eunmi , Bae Seongman , Chung Hyemin , Cho Eunbeen , Lee Sang-Oh , Choi Sang-Ho , Soo Kim Yang , Kim Sung-Han , Hee Woo Jun , Jung Jiwon , Jae Kim Min , Sung Heungsup , Kim Mi-Na , Park Su-Jin , Pil Chong Yong
Published: October 2019

Background

Carbapenem-resistant Enterobacteriaceae (CRE) infection is an emerging clinical issue. One of the mechanisms of carbapenem-resistance is carbapenemase production. This study aimed to identify whether clinical outcomes differ by CRE resistance mechanism and to evaluate risk factors for mortality in patients with CRE bacteremia.

Methods

We conducted a retrospective cohort study comparing 14-day mortality between patients with carbapenemase-producing (CP)-CRE and non-CP-CRE bacteremia during January 2011 to October 2018. Only monomicrobial Escherichia coli or Klebsiella pneumoniae bacteremia were included in the study. A modified carbapenem inactivation method was used for phenotypic detection of carbapenemase production. The presence of a variety of carbapenemase genes was evaluated by PCR with specific primers.

Results

Of 134 patients with monomicrobial CRE bacteremia, 48 (35.8%) were infected with CP-CRE, and 86 (64.1%) were infected with non-CP-CRE. The most common carbapenemase in CP-CRE isolates was KPC (66.7%), followed by NDM-1 (18.8%), OXA-48-like (10.4%), and VIM (4.1%). Baseline characteristics were similar between the two groups (Table 1). However, the CP-CRE group was significantly more likely to undergo removal of eradicable foci and to have meropenem MIC >8 µg/mL. A total of 33 (24.6%) patients died within 14 days, including 9 (18.8%) in the CP-CRE group and 24 (27.9%) in the non-CP-CRE group. Deceased patients were more likely to have a higher Pitt bacteremia score, nosocomial acquisition, ineradicable or not-eradicated foci, immunosuppressant use, inappropriate definitive treatment (Table 2). Combination therapy for definitive treatment was associated with decreased mortality. In a multivariate analysis including carbapenemase production, a higher Pitt bacteremia score (aOR, 5.15), ineradicable or not-eradicated foci (aOR, 4.05) and combination therapy for definitive treatment (aOR, 0.35) were independent risk factors for mortality.

Conclusion

Our study suggests that carbapenemase production is not a mortality risk factor in CRE bacteremia and provides additional evidence for early source control and combination therapy.

Disclosures

All authors: No reported disclosures.
519. Multidrug-resistant Gram-Negative Bacteremia in Pediatric Patients: Is It Time to Change to Empiric Meropenem?
Authors: Mongkolrattanothai Kanokporn , Stach Leslie , Orbach Regina
Published: October 2019

Background

The rise of antimicrobial resistance among gram-negative (GN) pathogens has been dramatic nationally. Delayed initiation of active antimicrobial agents has been associated with poor outcomes. We aimed at evaluating the prevalence and treatment of multi-drug-resistant gram-negative (MDR-GN) bacteremia in our pediatric patients.

Methods

All episodes of GN bacteremia from 2017–2018 at our institution were retrospectively reviewed. GN defined as MDR in our study were carbapenem-resistant organisms (CRO), extended-spectrum β-lactamase (ESBL) producers, and GN that were resistant to cefepime and ≥2 classes of non-cephalosporin antimicrobial agents. Stenotrophomonas maltophilia was excluded. Ineffective empirical treatment (IET) is defined as an initial antibiotic regimen that is not active against the identified pathogen[s] based on in vitro susceptibility testing results.

Results

A total of 292 episodes of GN bacteremia were identified and 6 S. maltophilia were excluded. Of these, 29 bacteremic episodes in 26 patients were caused by MDR-GN organisms including 18 ESBL, 7 CRO, 1 ESBL and CRO, 3 non-ESBL/non-CRO cefepime-resistant MDR-GN. None of the CRO had carbapenemase genes detected. However, there was a patient with multiple sites of infection simultaneously with non-NDM CR Acinetobacter bacteremia and NDM-mediated CR-Klebsiella ventriculitis. The annual rate of MDR-GN bacteremia increased from 8% in 2017 to 12% in 2018. Almost half (48%) of episodes were community onset. Among these, all but one had underlying medical conditions with hospital exposure and most patients had central venous devices at the time of infection. 52% (15/29) episodes of MDR-GN bacteremia had IET. Despite IET, 47% (7/15) had negative blood cultures prior to initiation of effective therapy (6 ESBL and 1 P. aeruginosa). Various antibiotic regimens were used for CRO therapy as shown in Table 1.

Conclusion

In our institution, MDR-GN infection is increasing. As such, empiric meropenem is currently recommended in BMT or neutropenic patients with suspected sepsis. However, empiric meropenem must be used judiciously as its widely use will lead to more selection of MDR pathogens. It is essential to continue monitoring of these MDR-GN to guide appropriate empiric regimens.

Disclosures

All authors: No reported disclosures.
520. The Clinical Profile and Outcomes of Patients given Intravenous Colistin for Multidrug-Resistant Gram-negative Infections in a Philippine Tertiary Hospital
Authors: Li Kingbherly L , Abad Cybele Lara R
Published: October 2019

Background

Colistimethate sodium (colistin) is used to treat multi-drug-resistant Gram-negative infections. We describe the profile and outcomes of patients given colistin in a tertiary level government hospital.

Methods

We performed a retrospective cross-sectional study of patients from the Philippine General Hospital given intravenous colistin between January 2015 to June 2018. Adult patients who received colistin for at least 24 hours and not on dialysis were included. Clinical success was defined as a composite of hemodynamic stability, stable quick Sequential Organ Failure Assessment score (qSOFA), and microbiological cure. Overall in-hospital mortality was recorded.

Results

We included 250 patients during the study period. The median age was 55 (19–91) years, 55.6% (139/250) were male, and 49.2% (123/250) were admitted in the intensive care unit (ICU). 77.2% (193/250) had at least one comorbidity, with solid-organ malignancy (27.6%, 69/250) being the most common. Most patients had at least one invasive device, commonly a nasogastric tube (64.4%, 161/250) or mechanical ventilator (63.2%, 150/250). There was an increase in Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II score, qSOFA, and septic shock from baseline to 24 hours prior to colistin use (Table 1). The most common site of infection was the respiratory tract (90.8%, 227/250). Majority of patients (78.8%, 197/250) had Acinetobacter baumannii infection of which 79.9% were extensively drug-resistant (XDR), susceptible only to colistin and amikacin or minocycline. Colistin was given for a mean of 12 (2- 43) days, concomitant with meropenem in 96.4% (241/250). Most patients received piperacillin–tazobactam (59%, 142/250) and/or meropenem (58%, 138/250) within the same admission. Nephrotoxicity (30.8%, 77/250) was the most frequent adverse effect (Table 2). Renal replacement therapy was needed in 6% (15/250) patients. Clinical success was seen in 61.2% (153/250) patients and overall mortality was 41.6% (104/250).

Conclusion

Colistin was frequently used in combination with a carbapenem for treatment of XDR-related respiratory infection or septic shock. Nephrotoxicity was a common adverse effect. The clinical success rate was modest and overall mortality was high.

Disclosures

All authors: No reported disclosures.
534. Active Screening for Carbapenemase Producing Enterobacteriaceae: Yield and Cost Considerations
Authors: Ramos-Castaneda Jorge A , Reeme Allison , Buchan Blake W , Ledeboer Nathan A , Beth Graham Mary , Pintar Paula , Singh Siddhartha , Silvia Munoz-Price L
Published: October 2019

Background

During 2016, our hospital experienced an outbreak with carbapenemase-producing Enterobacteriaceae (CPE) in our solid-organ transplant (SOT) population. Since this outbreak and until now, our hospital has implemented active CPE screening of patients admitted to SOT units and point prevalence surveillances in any unit with a known CPE patient. The present study evaluates the yield of these screening tests and their cost since implementation.

Methods

This retrospective cohort was performed in a 600-bed hospital in Milwaukee, WI. CPE screening tests were retrieved from the clinical microbiology laboratory dataset from January 2016 to April 2019. CPE tests are performed on rectal swabs or stool samples using the CDC broth enrichment method followed by MIC confirmation using Etest. CPE patients were placed on enhanced precautions (gowns, gloves, booties) and were cohorted geographically and to 1:1 nursing and nurse aid staff.

Results

A total of 6,684 samples belonging to 3,383 patients were processed (1.9 samples/patient). Two hundred thirty (3.44%) had carbapenem-resistant Enterobacteriaceae, although only 33 isolates (0.49%) were confirmed as either KPC (n = 31) or NDM (n = 2) positive. Out of the 3,383 patients tested, 121 were identified as carriers of carbapenem-resistant isolates but only 11 (0.32%) were CPE (KPC = 11; NDM = 2). The incidence of new CPE patients during 2016 was 0.82% but decreased to 0.28% and 0.33% in 2017 and 2018, respectively. The units with the highest number of CPE patients were the transplant intensive care unit (n = 6) and the step-down SOT unit (n = 3). Negative cultures were quoted at $8.49 per sample but culture plates with colonies increased the cost per test to $28.44. The total cost for all the 6,684 screening tests was calculated at $61,335. The cost of CPE screening per positive CPE patient identified comes up to $5,575 (not including RN collection time).

Conclusion

In an institution with staff and CPE patient cohorting, active screening of CPE positive patients was relatively expensive given our low -level of transmission. In the near future, we plan to stop staff and patient cohorting due to the high stress that these interventions place on our hospital staff. This might ensue in increase transmission, which will be detected by CPE screening tests.

Disclosures

All authors: No reported disclosures.
542. Los Angeles County Acute Care Regional Antibiogram Suggests Changing Landscape of MDRO Threats Between 2015 and 2017
Authors: McKinnell James , Foo Chelsea , OYong Kelsey , Hindler Janet , Ceja Sandra , Bloomfield Leah , Felix-Mendez Joanna , Tchakalian Gregory , Hurtado Aura , Eliopulos Alyssa , Sinkowitz Jake , Torres Crystal , Richter Stefan , Ha David
Published: October 2019

Background

National surveillance for multidrug-resistant organisms (MDRO) are limited by narrow geographic sampling, few hospitals, and failure to account for local epidemiology. A Los Angeles County (LAC) regional antibiogram was created to inform public health interventions and provide a baseline for susceptibility patterns countywide. We present data to compare the 2015 and 2017 LAC regional antibiogram.

Methods

We conducted a cross-sectional survey of cumulative facility-level antibiograms from all hospitals in LAC; 83 hospitals (AH) and 9 Long-term Acute Care (LTAC). For 2015, submission was voluntary, 2017 data were collected by public health order. Non-respondents were contacted by phone and in person. Isolates from sterile sources were pooled. Countywide susceptibility was calculated by weighting each facility’s isolate count by its reported susceptibility rate with minimum–maximim observed (2015) and Interquartile range (IQR) for 2017. Change from 2015 mean susceptibility is reported.

Results

Seventy-five (75) facilities submitted antibiograms for 2015 and 86 facilities for 2017. Among non-respondents in 2017, two facilities could not provide an adequate antibiogram and 4 were specialty hospitals with too few cultures to create an antibiogram. Regional summmary tables are presented in Tables 1–4. Klebsiella pneumoniae (n = 50 hospitals/19,382 isolates) % S to meropenem was 97% (IQR 94–100%), no change from 2015. Pseudomonas aeruginosa (PA) (n = 52 hospitals/17,770 isolates)% S to meropenem was 84% (IQR 74–93%), no change from 2015. Susceptibility to Acinetobacter baumannii (AB) was reported by 48 hospitals, including 1,4361 isolates,% S to meropenem was 39% (IQR 25–75%), 14% lower than 2015. Streptococcus agalactiae (n = 13 hospitals/647 isolates)% S to clindamycin was 43% (IQR 13–59%), a 22% increase from 2015.

Conclusion

LAC regional antibiograms identified stable patterns of antimicrobial resistance for most pathogens, but concerning results with AB and PA. Analysis of highly drug-resistant pathogens such as AB and PA would be improved with patient-level data to generate a combination antibiogram. We favor presenting IQR %S as done for 2017. Ongoing analysis will include multivariable analysis of observed changed S controlling for hospital characteristics.

Disclosures

All authors: No reported disclosures.
544. Clonal Spread of Two Sequence Types of Carbapenem-Resistant Acinetobacter baumannii Blood Isolates at a Tertiary Care Hospital in South Korea Over 2.5 Years
Authors: Eun Kim Seong , Choi Su-Mi , Yu Yohan , un Shin Sung , hoon Oh Tae , Jin Kim Uh , Kang Seung-Ji , Jang Hee-Chang , Park Kyung-Hwa , In Jung Sook
Published: October 2019

Background

The dissemination of carbapenem-resistant Acinetobacter baumannii (CRAB) became an urgent public health concern. A specific sequence type (ST) of A. bauamannii has been reported to be associated with severity of disease or mortality. This study aimed to determine the genetic relatedness of CRAB blood isolates cultured from patients at a tertiary care hospital and to investigate clinical characteristics and outcome of CRAB bacteremia.

Methods

CRAB blood isolates were collected between June 2016 and December 2018, and their clinical data were obtained. Multi-locus sequence test (MLST) was performed using the Oxford scheme, and the STs were assigned using the MLST database.

Results

Of the 126 CRAB blood isolates, 123 isolates which could be typed by MLST all belonged to clonal complex (CC) 92. During the entire period, ST369 (42.3%) was the most dominant, followed by ST191 (32.5%), ST784 (13.8%) and ST451 (4.1%). ST369 was firstly introduced in August 2017. ST191 (61.4%) was the most abundant during June 2016 to July 2017, whereas ST369 (65.8%) replaced ST191 (16.5%) since August 2017. The time interval between intensive care unit admission and bacteremia was shorter in ST369 than ST191 in multivariate analysis (day, median (Q1, Q3), ST369 6 (3, 9.8), ST191 9 (6, 17), Odd Ratio 0.87 (95% CI 0.76–0.99) P = 0.048 logistic regression). According to the ST, the 7-day and 30-day mortality rates were as follows; 46% and 65% in ST191, 50% and 62% in ST369, and 10.7% and 46.4% in the other STs. Patients infected by ST191 or 369 had significant higher 7-day mortality rates (ST191/369, 48.3% vs. the other STs 10.7%, P = 0.001 by log-rank test) and 30-day mortality rates (ST191/369, 63.2% vs. the other STs, 46.4%, P = 0.045 by log-rank test).

Conclusion

This study demonstrates the clonal spread of two STs at a tertiary care hospital in South Korea over 2.5 years. After the introduction of ST369, it replaced ST 191 and widely disseminated within a hospital. Two predominant STs were associated with poor outcome. Continuous surveillance are necessary to monitor the dissemination of these strains.

Disclosures

All authors: No reported disclosures.